Sections
Excerpt
Venlafaxine was developed as the first selective serotonin–norepinephrine reuptake inhibitor (SNRI) in the late 1980s and early 1990s (Bolden-Watson and Richelson 1993; Muth et al. 1986). Several early randomized controlled trials (RCTs) confirmed that venlafaxine had antidepressant effects comparable to those of tricyclic antidepressants (TCAs), with fewer side effects attributable to anticholinergic and antihistaminergic activity (see, e.g., Einarson et al. 1999). An immediate-release (IR) form of venlafaxine was approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in 1994, and the extended-release (XR) formulation was introduced in 1997. Made available after several widely prescribed newer-generation antidepressants (e.g., fluoxetine, sertraline, paroxetine), venlafaxine became one of the leading alternatives for patients who do not respond to selective serotonin reuptake inhibitors (SSRIs).
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
